Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01358266 · ClinicalTrials.gov registry record · Phase 3
Study Assessing Double-masked Uveitis Treatment
A Phase 3 study, sponsored by Santen.
- Completed
- Registry status
- Phase 3
- Development phase
- 592
- Enrollment target
NCT01358266: Completed Phase 3 study, sponsored by Santen.
NCT01358266 is a Phase 3 study that has completed, run by Santen. The registered enrollment target is 592 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (23% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01358266, a Phase 3 study, has completed, sponsored by Santen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 592 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of intravitreal injections of DE-109 ophthalmic solution.
Primary Outcome
At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Description VH score 0 = No inflammation
Interventions
- DRUG DE-109 44 ug
- DRUG DE-109 440 ug
- DRUG DE-109 880 ug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 592 participants |
| Start Date | 2011-05 |
| Est. Completion | 2016-12 |
| Phase | Phase 3 |
What the finished NCT01358266 record still lists
NCT01358266 is an interventional study that assigns participants to a tested intervention. The registered 592 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (23% lower).
The record links to 0 conditions, and to 3 interventions - of which DE-109 44 ug is the first listed.
NCT01358266 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01358266 about?
NCT01358266 is a clinical study titled "Study Assessing Double-masked Uveitis Treatment". The purpose of this study is to evaluate the safety and efficacy of intravitreal injections of DE-109 ophthalmic solution.
What is the current status of trial NCT01358266?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 592 participants. The study started on 2011-05. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01358266?
The interventions under investigation include: DE-109 44 ug (DRUG), DE-109 440 ug (DRUG), DE-109 880 ug (DRUG).
Who is sponsoring clinical trial NCT01358266?
This trial is sponsored by Santen, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01358266's enrollment target sits among peer trials
592 643rd of 2000 higher than 1,358 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04701684 · 594 participants · NA
WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)
- NCT05491213 · 594 participants · NA
TELESCOPE- TELEhealth Shared Decision-making COaching
- NCT05867420 · 594 participants · Phase 1
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
- NCT06890884 · 594 participants · Phase 2
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia